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Abstract
Background. In Fabry nephropathy, alpha-galactosidase
deficiency leads to accumulation of glycosphingolipids in
all kidney cell types, proteinuria and progressive loss of
kidney function.
Methods.An international working group of nephrologists
from 11 Fabry centres identified adult Fabry patients, and
pathologists scored histologic changes on renal biopsies. A
standardized scoring systemwas developedwith amodified
Delphi technique assessing 59 Fabry nephropathy cases.
Each case was scored independently of clinical information
by at least three pathologists with an average final score
reported.
Results.Weassessed 35males (mean age 36.4 years) and 24
females (43.9 years) who mostly had clinically mild Fabry
nephropathy. The average serum creatinine was 1.3 mg/dl
(114.9 μmol/l); estimated glomerular filtration rate was
81.7 ml/min/1.73 m2 and urine protein to creatinine ratio
was 1.08 g/g (122.0 mg/mmol). Males had greater podocyte
vacuolization on light microscopy (mean score) and gly-
cosphingolipid inclusions on semi-thin sections than fe-
males. Males also had significantly more proximal tubule,
peritubular capillary and vascular intimal inclusions. Arte-
riolar hyalinosis was similar, but females had significantly
more arterial hyalinosis. Chronic kidney disease stage cor-
related with arterial and glomerular sclerosis scores. Sig-
nificant changes, including segmental and global sclerosis,
and interstitial fibrosis were seen even in patients with stage
1–2 chronic kidney disease with minimal proteinuria.
Conclusions. The development of a standardized scoring
system of both disease-specific lesions, i.e. lipid deposition
related, and general lesions of progression, i.e. fibrosis and
sclerosis, showed a spectrumof histologic appearances even
in early clinical stage of Fabry nephropathy. These findings
support the role of kidney biopsy in the baseline evaluation
of Fabry nephropathy, even with mild clinical disease. The
scoring systemwill be useful for longitudinal assessment of
prognosis and responses to therapy for Fabry nephropathy.
Keywords: chronic kidney disease; Fabry disease; pathology; sclerosis;
scoring
Introduction
Fabry disease is an X-linked genetic disorder with cellu-
lar accumulation of globotriosylceramides (GL-3) due to
lysosomal alpha-galactosidase enzyme activity deficiency
[1,2]. Males classically develop chronic kidney disease
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(CKD) and progress to end-stage renal disease (ESRD) be-
fore their fifth decade [1–3]. Enzyme replacement therapy
(ERT) reduces GL-3 deposits [4–6] and slows progression
of Fabry nephropathy [7].
Females have variable disease severity [1]; they can
be asymptomatic, but most of them develop clinically
apparent disease [8,9] and risk premature death [10].
Proteinuria and/or reduced glomerular filtration rate
(GFR) may be found in 40% of adult females [8,11], and
some are severely affected, reaching ESRD at the same
median age as males [3,11].
Renal intracellular GL-3 deposits are present, even in pa-
tients with normal GFR and minimal proteinuria [12,13].
Vacuolization of podocytes and epithelial cells is a char-
acteristic histologic finding [12,14–16]. Mesangial expan-
sion, segmental and global glomerulosclerosis, tubular at-
rophy and interstitial fibrosis are also seen, even in early
stages of the disease [12–17]. The original descriptions of
Fabry nephropathy were in males [16]. Females can de-
velop the same kidney histopathology as males [12,16,18],
but fewer female cases have been described [12,15,16,
18–20].
We systematically scored histologic lesions in kidney
biopsies in a set of 35 adult males and 24 adult females with
Fabry disease, the majority with clinically mild nephropa-
thy. In addition, a morphometric index of chronic damage
was obtained for each biopsy [21]. A validated scoring sys-
tem was developed, with the long-term goal to determine
whether baseline histologic information can be related to
the rate of progression and/or response to ERT in Fabry
nephropathy.
Subjects and methods
The International StudyGroup of FabryNephropathy (ISGFN)was formed
by pathologist and nephrologist pairs, from 10 different major referral
centres for Fabry disease, and by a central nephropathology site (Dr A.B.
Fogo, Nashville, TN, USA). The central site coordinated the collection,
distribution and circulation of available biopsies among the participating
centres and data entry into a computerized database. Kidney biopsies were
from white adults with the diagnosis of Fabry disease, as confirmed by
mutational analysis of the alpha-galactosidase gene.
Clinical assessments
Demographic and clinical data were abstracted from the clinical records
closest to the time of the biopsy. Biopsies were performed between
January 1999 and September 2006. GFR was estimated (eGFR) with
the Modification of Diet in Renal Disease simplified equation [22].
Urine protein values were expressed as urine protein/creatinine ratios
(UPCR). When only 24-h protein measurements were available, daily
creatinine excretions were estimated as the product of eGFR and serum
creatinine.
Histological scoring
General approach. Disease-specific GL-3 storage-related and nonspe-
cific histologic features of Fabry nephropathy were included in the score
sheet (see Appendix for details). The scoring matrix was developed and
refined in several round-robin slide reviews and face-to-face scoring ses-
sions, using a modified Delphi technique [23].
Biopsies were coded and the exact tissue sections to be scored were
marked on the slides at the central site, and slides were distributed on a
blinded basis for review.A subset of 20 representative biopsieswas initially
circulated to all centres for training and scoring validation. Subsequent
scoring was done by three centres for each case.
Interstitial fibrosis and index of chronic damage. In addition to the semi-
quantitative histologic assessment on interstitial fibrosis, the index of
chronic damage was morphometrically determined for each biopsy.
Statistical analysis
The results are presented asmean± standard deviation (SD), withmedians
and ranges where indicated. Bivariate determinations are presented as
percentages of the number scored or enumerated. Trend analysis was done
with linear regression of the median of variables for each CKD stage [24]
against the stage ordinal (stages 4 and 5 were combined).
The reliability of the scoring among the pathologists was assessed
with intraclass correlation coefficient (ICC) analysis [25,26] for the semi-
quantitative assessment of interstitial fibrosis and morphometric assess-
ment of the chronic damage index, and for the podocyte vacuolization on
periodic acid Schiff-stained light microscopic sections and podocyte GL-3
deposits on semi-thin sections stained with toluidine blue. Because each
case was not scored by every pathologist, a generalization of the standard
linear model that allows for fixed and random effects was used for ICC
analysis instead of analysis of variance [27].
The interclass correlation, using Spearman’s correlation coefficient,
was used to compare the overall assessment of interstitial fibrosis ob-
tained with semi-quantitative scoring by the pathologists with the scores
obtained for the same cases using a published morphometric technique
[21]. The semi-quantitative andmorphometric scores of interstitial fibrosis
also underwent Bland–Altman analysis [28]. Interclass correlations, using
Spearman’s correlation coefficient, were also used to compare the overall
assessment of podocyte vacuoles on light microscopy with podocyte GL-3
inclusions on semi-thin sections.
Statistical comparisons were done with unpaired two-tailed t-tests and
two-tailed Fisher exact tests. The F-statistic was used to evaluate the
significance of trends. P-values < 0.05 were considered to be significant.
Calculations were carried out with SAS, version 9.1 (SAS Institute, Inc.
Cary, NC, USA).
Results
Summary of clinical assessments
All patients had defined mutations, and five male pa-
tients had the p.N215S missense mutation, previously de-
scribed in the late-onset cardiac variants of Fabry disease
[1]. The mean age was 39.4 ± 13.2 years (range 16–70),
and the serum creatinine was 1.3 ± 1.2 mg/dl (range 0.6–
7.1) [114.9 ± 106.1 μmol/l (range 53.0–627)]. UPCR was
1.08± 1.34 g/g (range 0.01–5.62) [122.0± 151.4mg/mmol
(range 1.1–635.1)] (Table 1). Forty-six patients (78.0%,
25 males) had stage 1 or 2 CKD, 8 (13.6%, 7 males) had
stage 3 CKD and 5 males (8.5%) had stage 4 or 5 CKD
(Table 2). Males with CKD stage 1 were significantly
younger than the females (28.1 ± 10.3 versus 42.4 ± 10.6
years, P < 0.003).
Average systolic and diastolic blood pressures were
125.7 ± 13.0 (range 100–167) and 75.6 ± 10.5 mmHg
(range 54–105; Table 1), respectively. Systolic blood pres-
sure was >135 mmHg in 13 (22%) patients, and diastolic
blood pressure was >85 mmHg in 9 patients (15.3%).
Angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers were given to 24 patients (40.7%).
Nine patients started ERT 1.5 ± 1.0 months (range 0.6–
3.9, median 1.4) before biopsy at a dose of 0.2 (n = 3) or
1.0 mg/kg every 2 weeks (n = 6). Forty-six patients started
ERT 8.2± 13.1 months (range 0.03–76.2, median 4.0) after
biopsy at a dose of 0.2 (n= 13) or 1.0 mg/kg every 2 weeks
(n = 33).
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Table 1. Values are presented as mean ± SD and median, and (range; median) for UPCR
All patients (n = 59) Male (n = 35) Female (n = 24) P-value
Age (years) 39.4 ± 13.2 (40.0) 36.4 ± 14.0 (37.0) 43.9 ± 10.6 (43.5) 0.030∗
Serum creatinine (mg/dl) 1.3 ± 1.2 (0.9) 1.6 ± 1.4 (1.2) 0.8 ± 0.2 (0.8) 0.007∗
eGFR (ml/min/1.73 m2)
UPCR (g/g)
81.7 ± 34.8 (81.9)
1.08 ± 1.34
79.0 ± 42.3 (80.0)
1.28 ± 1.48
85.8 ± 19.6 (84.0)
0.80 ± 1.09
NS
(0.01–5.62; 0.42) (0.04– 5.62; 0.51) (0.01–3.47; 0.17) NS
Systolic BP (mmHg) 125.7 ± 13.0 (126.0) 126.1 ± 13.1 (125.0) 125.3 ± 13.3 (129.0) NS
Diastolic BP (mmHg) 75.6 ± 10.5 (75.0) 74.3 ± 11.5 (73.0) 77.4 ± 8.9 (77.5) NS
Values are presented as mean ± SD and median, and (range; median) for UPCR. To convert UPCR to mg/mmol, multiply by 113.12.
∗P-values; males compared to females, two-tailed t-test.
eGFR, estimated glomerular filtration rate; UPCR, urine protein to creatinine ratio; BP, blood pressure; NS, non-significant.
Table 2. Summary of patient characteristics by CKD stage
Stage 1 Stage 2 Stage 3 Stages 4, 5
Males (n) 15 8 7 5
Age (years) 28.1 ± 10.3 39.9 ± 14.1 46.4 ± 11.3 41.5 ± 16.6
eGFR 119.1 ± 21.9 73.4 ± 7.8 43.9 ± 8.9 16.3 ± 10.3
UPCR 0.73 ± 0.83
(0.04–2.39; 0.37)
0.81 ± 0.85
(0.04–2.18; 0.55)
0.86 ± 0.59
(0.20–1.97;0.71)
4.23 ± 1.25
(2.3–5.6; 4.29)
Females (n) 10 13 1 0
Age (years) 42.4 ± 10.6∗ 43.5 ± 9.9 63.0 NA
eGFR 104 ± 12.8 74.8 ± 8.4 46.0 NA
UPCR 0.44 ± 0.48
(0.04–1.46; 0.24)
1.00 ± 1.36
(0.01–3.47; 0.15)
1.83 NA
Values are presented as mean ± SD and (range; median).
eGFR, estimated glomerular filtration rate (ml/min/1.73 m2); UPCR, urine protein to creatinine ratio (g/g; to convert to mg/mmol, multiply by 113.12.);
NA, not applicable.
∗P < 0.003; males compared to females, two-tailed t-test.
Biopsy findings
The histologic evaluations are summarized in Tables 3–
6. On average, 16.1 ± 11.9 glomeruli were present for
light microscopic assessment (range 1–67), and 2.6 ± 1.9
(range 0–8) glomeruli were examined on toluidine blue-
stained semi-thin sections. Two cases were not scored on
the semi-thin sections because of inadequate staining.
Glomerular sclerosis. There was a wide range of
glomerular sclerosis scores (Table 3). Mild or severe seg-
mental sclerosis was observed in 19 of 35 males (9 stage
1 CKD, 3 stage 2 CKD, remainder with more advanced
CKD), and 11 of 24 females (2 stage 1 CKD, 8 stage 2
CKD, 1 patient with more advanced CKD). The average
extent of segmental sclerosis was 4.7 ± 7.8% of glomeruli,
withmild and severe lesions seen in the same biopsy. Global
sclerosis was present in 14.8 ± 22.7% of glomeruli. Ten of
the 15 males (66.7%) with stage 1 CKD had segmental
or global sclerosis in 6.2 ± 8.7% (median 2.9) of their
glomeruli, and 7 of the 10 females with stage 1 CKD had
segmental or global sclerosis in 5.7± 9.0% (median 3.0) of
their glomeruli. On average, 43.5± 23.0% of the glomeruli
had global sclerosis for the 13 patients with eGFR <60
ml/min/1.73 m2, with only 1 without global sclerosis.
Interstitial fibrosis and chronic damage index. The semi-
quantitative and morphometric scores for fibrosis were
closely correlated (top section, Table 4; Spearman’s co-
efficient = 0.871, P < 0.001). Bland–Altman analysis
Fig. 1. Interstitial fibrosis (%): comparison of semi-quantitative scoring
to morphometric assessment. Bland–Altman plot compares the difference
(index of chronic damage – semi-quantitative score; solid horizontal line)
with their mean. The limits of agreement (±2 SD) are shown as dashed
horizontal lines.
(Figure 1) [28] showed that the semi-quantitative assess-
ment had no significant bias compared to the morphometry
(mean difference of average score minus index of chronic
damage = +0.79%; 95% Confidence Interval; −1.74
to +3.32%). The limits of agreement (mean difference
± 2 SD) ranged between −18.6% and 20.2%.
The reliability of scoring among the pathologists was as-
sessed with ICC analysis [25,26]. The variance in scoring
attributable to the cases and the residual variance were used
to estimate the ICC (0.6539). The variance within cases
was 52.9% of the variance between cases (Table 4), in-
dicating reasonably good agreement between the different
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Table 3. Kidney morphologic findings in Fabry patients
All (n = 59) Male (n = 35) Female (n = 24)
Glomeruli, number in biopsy (light microscopy sections) 16.1 ± 11.9 (13.6) 17.3 ± 12.8 (14.3) 14.3 ± 10.3 (13.6)
Segmental sclerosis; (mild + severe) (%) 4.7 ± 7.8 (0.9) 5.1 ± 8.5 (1.9) 4.0 ± 6.7 (0.0)
Global sclerosis (%) 14.8 ± 22.7 (2.9) 18.3 ± 24.3 (5.9) 9.8 ± 19.5 (0.5)
Glomeruli without sclerosis (%) 69.9 ± 27.3 (75.2) 66.3 ± 30.4 (75.2) 75.2 ± 21.6 (77.7)
Interstitial fibrosis (%) 16.2 ± 22.9 (6.0) 20.4 ± 25.0 (10.0) 10.1 ± 18.3 (2.5)
Arterial sclerosis (0–3) 0.71 ± 0.72 (0.43) 0.75 ± 0.77 (0.33) 0.64 ± 0.66 (0.47)
Podocyte vacuoles (light microscopy; 0–3)∗ 2.2 ± 0.8 (2.5) 2.3 ± 0.7 (2.6) 1.9 ± 0.8 (1.9)
Podocyte inclusions (semi-thin sections; 0–4)∗ 3.0 ± 1.2 (3.5) 3.3 ± 1.1 (3.9) 2.4 ± 1.2 (2.8)
Values are presented as mean± SD and (median). Assessment from standard light microscopy sections unless otherwise indicated. Percentage represents
proportion of glomeruli with lesion. Of note, glomeruli with periglomerular fibrosis, extensive corrugation, ischaemia or adhesion were not scored as
‘non-sclerotic’, and thus the sum of global or segmental sclerosis and ‘non-sclerotic’ glomeruli does not necessarily equal 100%.
∗P < 0.03, two-tailed t-test, females compared to males.
Table 4. Interclass and intraclass correlation coefficients for interstitial fibrosis, podocyte vacuoles and podocyte GL-3 inclusions
Scoring (n) Mean (%) SD Median Minimum Maximum
Morphometric score (59) 16.22 22.94 6.00 0 89.0
Average semi-quantitative score (59) 17.01 10.56 8.33 0 75.0
Spearman’s interclass correlation coefficient = 0.871, P < 0.001
Scoring (scale) Mean (%) SD Median Minimum Maximum
Podocyte vacuoles (1–3) 2.19 0.80 2.5 0 3.00
Podocyte inclusions (1–4) 2.95 1.21 3.4 0 4.00
Spearman’s interclass correlation coefficient = 0.5774, P < 0.0001
Scoring (n) Variance of cases (V) (SE) Residual variance (R) (SE) ICC (V/V+R) Within case
variance(1-ICC)/ICC
Interstitial fibrosis score (59) 340.3 (71.8)∗ 180.1 (18.9)∗ 0.6539 52.9%
Podocyte vacuoles (59) 0.557 (0.119)∗ 0.235 (0.0310)∗ 0.7030 42.2%
Podocyte inclusions (57) 1.344 (0.278)∗ 0.3443 (0.047)∗ 0.7961 25.7%
∗P < 0.0001.
ICC, intraclass correlation coefficient; R, residual variance; V, variance of cases.
pathologists with respect to the semi-quantitative scoring
of interstitial fibrosis.
Podocytes vacuoles and inclusions. Vacuoles were fre-
quently observed in podocytes (Figure 2A), corresponding
to extracted GL-3 deposits. Vacuole average severity (0–3
scale) was 2.3 ± 0.7 (median 2.6) for males and 1.9 ±
0.8 (median 1.9) for females (P < 0.03, Table 3). GL-3
inclusions were scored for the semi-thin sections stained
with toluidine blue (0–4 scale). The distribution of GL-3
inclusions was quite variable (Figure 2B and C). Women
had significantly fewer deposits than men (2.4± 1.2 versus
3.3 ± 1.1; P < 0.03; Table 3). The most common pattern
in male patients was a mixture of large expanded deposits
with concurrent small deposits.
Of patients with glomeruli available on semi-thin sec-
tions, one 46-year-old woman did not have any GL-3 de-
posits, and seven additional female patients and one male
patient had small deposits (i.e. inclusion score <1.5); none
had received ERT. The female patient without podocyte de-
posits had distal tubular and arterial medial deposits and
was known to have mutation p.R363P. Parietal epithelial
inclusions were present (Figure 2B), but were not reliably
scored.
The podocyte vacuole scores and GL-3 inclusion scores
agreed reasonably well (Table 4). The reliability of the scor-
ing among the pathologists was assessed with ICC analysis
[25,26]. The variance attributable to the cases, and the resid-
ual variance were used to estimate the ICC. The variance
component within cases was 42.2% and between cases was
25.7%, respectively, for the scorings of podocyte vacuoles
on light microscopy and GL-3 inclusions on semi-thin sec-
tions. Of the three ICC comparisons, the reliability of the
scoring of the podocyte GL-3 inclusions appeared to be su-
perior to the semi-quantitative scoring of interstitial fibrosis
or podocyte vacuoles.
Tubular inclusions. Distal tubule inclusions were present
in 42 of the 56 cases (75.0%) (Table 5, Figure 2D–F).
Proximal tubule inclusions were more prevalent in males
than females (47.1% versus 19.0%, P = 0.046). Inclusions
in both proximal and distal tubules were present in 14males
and 4 females, and 14 males and 9 females only had distal
tubule inclusions.
Capillary and arterial inclusions. Peritubular capillary
inclusions were identified in 26 males and 7 females
(P = 0.002). Intimal vascular inclusions were more preva-
lent in males than females. Vascular medial inclusions were
present in 25 out of 38 patients (Figure 3). Lesions included
typical arteriosclerotic lesions and severe medial injury and
necrosis with inclusions, often associated with luminal di-
latation. Arterial sclerosis was mild (Table 3). Hyalinosis
was present in arterioles of 34 patients and in arteries of 22
patients out of 55 evaluated (Table 5). Arteriolar hyalinosis
was scored in 22 of 34 males (64.7%) and 12 of 21 females
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Fig. 2. Vacuolization and glycosphingolipid deposits in Fabry nephropathy. (A) The glomerulus shows vacuolization of podocytes (arrowheads), and
mild corrugation of glomerular basement membranes, with periglomerular and interstitial fibrosis (periodic acid-Schiff, x400). (B) The glomerulus
shows massive expanded deposits in most podocytes (arrowheads) and also in mesangial and endothelial cells and parietal epithelial cells in this male
Fabry patient (toluidine blue, ×400). (C) The glomerulus shows occasional small deposits in podocytes (arrowheads) and rare deposits in mesangial
areas in this female patient (toluidine blue,×400). (D) There are prominent deposits in some proximal tubular cells and peritubular capillary endothelium
(toluidine blue, ×1000). (E) Numerous deposits in distal tubules and very rare deposits in proximal tubules. The vascular smooth muscle of a large
artery (top left corner) also shows deposits, as do parietal epithelial cells lining the Bowman’s capsule (bottom) (toluidine blue, ×1000). (F) Numerous
deposits in distal tubules with rare deposits in proximal tubules and frequent deposits in peritubular capillaries and interstitium (toluidine blue, ×200).
Table 5. Kidney morphologic findings in Fabry patients
All (n = 59) Male (n = 35) Female (n = 24) P-valuea
Distal tubule inclusions 42/14 (75.0%) 28/6 (82.4%) 14/8 (63.6%) NS
Proximal tubule inclusions 20/35 (36.4%) 16/18 (47.1%) 4/17 (19.0%) 0.046
Peritubular capillary inclusions 33/23 (58.9%) 26/8 (76.5%) 7/15 (31.8%) 0.002
Vascular intimal inclusions 19/19 (50.0%) 16/9 (64.0%) 3/10 (23.1%) 0.038
Vascular medial inclusions 25/13 (65.8%) 17/8 (68.0%) 8/5 (61.5%) NS
Arteriolar hyalinosis (light microscopy sections) 34/21 (61.8%) 22/12 (64.7%) 12/9 (57.1%) NS
Arterial hyalinosis (light microscopy sections) 22/33 (40.0%) 9/25 (26.5%) 13/8 (61.9%) 0.012
Data are presented as present/absent and percentage present/(present + absent);
Excluded cases are those that could not be scored due to insufficient sampling for that variable. Lesions scored on semi-thin sections except as noted.
aFisher exact two-tailed test statistic, females compared to males;
NS, non-significant.
(57.1%). Arterial hyalinosis was present in 9 of 34 males
(26.5%) and 13 of 21 females (61.9%; P = 0.012).
Trend analysis. Arterial sclerosis was more severe with
advanced CKD (P = 0.0003), but blood pressure was not
correlated (not shown). Glomerular sclerosis was more se-
vere with more advanced CKD. In stage 1 CKD, 7.8 ±
17.6% (median 0.85) of the glomeruli had segmental or
global sclerosis despite minimal proteinuria.
Discussion
We have described the renal biopsies of mild Fabry
nephropathy in adult patients. Histologic evidence of kid-
ney involvement precedes clinical signs in early Fabry
nephropathy, confirming previous reports [16,17,19,29].
Glomerulosclerosis and interstitial fibrosis were observed
in both genders, even in patientswithminimal or no protein-
uria in our series. In the evaluation of early Fabry nephropa-
thy, clinical assessments lack sensitivity, potentially delay-
ing initiation of ERT [30], highlighting the utility of kidney
biopsies as part of the baseline assessment.
A similar scoring strategy was used for lupus nephri-
tis [31] and focal segmental glomerulosclerosis [32]: in-
clusion of pathologists and clinicians; multiple iterations;
validation and adjudication of difficult lesions; and refine-
ment of definitions using amodified Delphi technique [23].
We evaluated disease-specific GL-3 lesions and secondary
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Table 6. Summary of trend analyses by CKD stage
Stage 1 (n = 25) Stage 2 (n = 21) Stage 3 (n = 8) Stages 4, 5 (n = 5) P-value∗
eGFR 113.1 ± 20.0 (110.0) 74.3 ± 8.0 (72) 44.2 ± 8.3 (45.5) 16.3 ± 10.3 (13.6) 0.002
Arterial sclerosis, 0–3 0.46 ± 0.68 (0.00) 0.62 ± 0.57 (0.50) 0.93 ± 0.39 (1.00) 1.93 ± 0.72 (1.66) 0.003
No sclerosis, % glomeruli 82.3 ± 18.7 (88.4) 74.5 ± 20.9 (78.8) 50.2 ± 28.9 (55.1) 20.7 ± 14.2 (21.7) 0.027
Mild + severe sclerosis, % glomeruli 2.8 ± 5.5 (0.00) 4.3 ± 6.5 (1.06) 6.9 ± 10.9 (1.35) 11.9 ± 13.2 (5.26) NS
Global sclerosis, % glomeruli 5.0 ± 17.1 (0.00) 8.7 ± 11.3 (5.9) 35.9 ± 24.9 (32.7) 55.5 ± 14.6 (50.0) 0.024
Mild + severe + global sclerosis, % glomeruli 7.8 ± 17.6 (0.85) 13.1 ± 15.7 (7.1) 42.9 ± 26.9 (46.4) 67.4 ± 11.6 (69.8) 0.030
Interstitial fibrosis, % 8.4 ± 15.9 (2.0) 9.4 ± 16.2 (3.0) 27.8 ± 19.7 (21.5) 65.6 ± 13.9 (61.0) 0.027
Values are presented as mean ± SD and (median).
eGFR, estimated glomerular filtration rate (ml/min/1.73 m2); NS, non-significant.
∗P-value for the regression calculated with the F-test; interstitial scores transformed as log(score) before analysis.
Fig. 3. Vascular lesions in Fabry nephropathy. Numerous inclusions in
endothelial cells and vascular smooth muscle cells in this large artery are
seen in the toluidine blue-stained semi-thick scout section (toluidine blue,
×1000).
alterations that occur in Fabry nephropathy [33], as well as
any other form of CKD (e.g. arterial and glomerular sclero-
sis, and interstitial fibrosis). Interstitial fibrosis, global and
segmental sclerosis and podocyte inclusions were robustly
scored. The latter parameter showed the highest degree of
inter-individual agreement. The semi-quantitative scoring
of interstitial fibrosis showed similar reliability when com-
pared to the morphometric assessment. Other lesions (e.g.
parietal epithelial cell inclusions, interstitial inflammation)
could not be reliably scored with the current approaches.
Glomerulosclerosis occurs early in Fabry nephropathy
and is more severe with more advanced CKD. Only 37% of
our patients with eGFR >60 ml/min/1.73 m2 did not have
any glomerular sclerotic lesions, and ∼13% had sclerosis
in >20% of glomeruli. Although proportions of segmen-
tal and global sclerosis varied among cases, no significant
histologic differences between genders could be identified
in early CKD. This finding may have important prognostic
implication; Germain et al. [6] have described a marked
loss of GFR in male Fabry patients with segmental and
global glomerular sclerosis in >50% of their glomeruli.
GL-3 inclusions in podocytes were larger in males than
in females, despite the 7.5-year higher mean age of fe-
males. Even in early CKD, half of the males had large
podocyte inclusions involving>50%of the glomerular tuft.
The podocyte scores for vacuolization and inclusions were
significantly correlated, with only two patients having dis-
cordant findings.
Most of our patients (78%) had mild nephropathy (stage
1–2 CKD). Nearly half of the stage 1–2 CKD patients were
females. Some conspicuous gender differences were ob-
served. Clinical disease was milder in the female cohort,
with corresponding lesser degree of global sclerosis and
less podocyte, peritubular, vascular and proximal tubule in-
clusions than in the males. However, segmental and global
glomerulosclerosis, interstitial fibrosis, distal tubular inclu-
sions, arteriolar hyalinosis and vascular medial inclusions
were of similar degrees in females as in males. Arterial
hyalinosis was the only lesion more prevalent in females
than males, which may be related to their higher mean age.
These gender differences indicate that prognostic scoring
elements may be assessed differently in male and female
Fabry patients. Arterial sclerosis increasedwith CKD stage,
and there appears to be a non-linear relationship between
interstitial fibrosis and CKD stage, with minimal fibrosis
scores in the stage 1–2 biopsies (Table 6).
Attempts to develop prognostic markers and/or
pathogenic insights from renal biopsies have been under-
taken in other forms of CKD. Glomerulosclerosis, intersti-
tial fibrosis, endocapillary proliferation and surprisingly,
mesangial proliferation were signs of poor prognosis in
IgA nephropathy [34]. In the African-American Study of
Kidney Diseases, global sclerosis was minimally related to
mean arterial pressure, but was predicted by systolic blood
pressure, serum cholesterol and reciprocal of serum crea-
tinine [35]. With longitudinal studies of Fabry patients, a
similar strategy may support the development of a chronic-
ity index that reflects the long-term outcome. The variables
summarized in Tables 3–5 may serve as the basis for such
studies. The amount of chronic renal damage at the time of
biopsy is likely to be related to the rate of loss of kidney
function [23]. In addition, some lesions may influence the
rate of decline, as well as baseline GFR. There may also
be an indication as to response to therapy for some of the
scored variables.
Several limitations of our study are evident. (1) We
have assigned CKD stages to the patients based on base-
line serum creatinine values and calculated eGFR. The
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majority of patients had GFR >60 ml/min/1.73 m2, be-
yond the current validation range of the MDRD. UPCR
was used as an index of proteinuria. KDOQI [24] defined
CKD as either kidney damage or eGFR <60 ml/min/1.73
m2 for ≥3 months, with kidney damage defined as patho-
logic abnormality or a marker of damage. Since all of our
patients had biopsy-proven Fabry nephropathy, we feel jus-
tified in using CKD staging to describe the severity of their
kidney damage. Furthermore, the significant increases in
the various sclerosis scores with CKD stage, with more se-
vere scores in stage 2 than stage 1 (Table 6), lend further
credence to the use of CKD staging, bearing in mind the
reservations about using estimating equations for GFR. (2)
Nine patients received ERT before biopsy, but the median
time before biopsy was only 1.4 months, with none more
than 4 months. It is not likely that short-term ERT would
influence sclerotic lesions. (3) Biopsies were performed
according to the local standard of care, and the criteria for
submitting cases for this study were not restrictive. This
retrospective, cross-sectional design raises a possible se-
lection bias for inclusion in the study. (4) Few patients with
advanced CKD were included, limiting the trend analysis
as well as comparisons between genders. Nevertheless, the
pathology was similar in both genders, although developing
at a later age in females.
The present study focused on histologic sections for de-
veloping the scoring system. For this purpose, standard
histologic sections provided sufficient glomeruli and more
extensive vascular and interstitial sampling, overcoming the
limited tissue sampling with semi-thin sections used in pre-
vious studies [5]. On the other hand, histological findings
suggestive of Fabry nephropathy (e.g. vacuolization) may
be missed on routine histologic sections; semi-thin sections
are best for characterizing podocyte GL-3 inclusions. This
conclusion is strengthened by the ICC analysis in Table 4.
In conclusion, our description and validation of a scor-
ing system of histologic involvement in Fabry nephropathy
are notable because of the inclusion of a large number of
adult females. Chronic glomerular and interstitial damage
develop early in the course of Fabry disease, and the ab-
sence of typical clinical signs of CKD does not rule out
Fabry nephropathy. Overall, our results are in agreement
with previous, smaller series of Fabry patients, showing
significant histologic changes before renal function is de-
creased [12,16,19]. Access to detailed illustrations and def-
initions of lesions (see Appendix) should enhance the util-
ity and application of the scoring system for future studies
of Fabry nephropathy. Future development of a chronic-
ity index based on longitudinal data may be useful for
describing severity of pathologic changes and prognostic
implications for progressive Fabry nephropathy. For now,
we conclude that important information is provided by kid-
ney biopsy in Fabry nephropathy that is not available from
routine assessment of kidney function and proteinuria. Our
results support the role of kidney biopsy in the baseline
evaluation of all Fabry patients, even with mild clinical
disease.
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Appendix. Histologic scoring
General approach
The initial effort involved six cases coded and blinded as to
origin of slides and was intended to identify common fea-
tures in the biopsies (fibrosis, sclerosis, vascular changes,
GL-3 deposits, etc.) that would be included in the final
scoring sheet. Round-robin slide reviews and two face-to-
face scoring sessionswith amodifiedDelphi technique [23]
were used to refine the scoring system. Then, slides from
20 cases were circulated, with each group scoring each ele-
ment specified in the score sheet (Figure A1). In a face-to-
face meeting, cases with difficult lesions were discussed
for further refinement and clarification of definitions.
This sequence of scoring, Delphi consensus process and
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Fig. A1. Scoring sheet for Fabry nephropathy by light microscopy.
rescoring, was adopted to validate the scoring system. The
final 59 cases were then circulated with each biopsy scored
by three different centres. Final scores of all 59 cases rep-
resent the average in each case from all validated scorings
from these centres. An average for each parameter was
calculated, with a range. For lesions scored as present or
absent, cases with divergent scoring were reviewed for a
final score by A.B.F. Electron micrographs were not exam-
ined in the current project. Morphometry was done on all
slides by one centre (see below).
Lesions were scored on the same sections on the circu-
lated slide, so that all observers assessed the exact same
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tissue. For most cases, tissue was assessed on periodic
acid-Schiff (PAS)-stained slides. In a few cases, when PAS-
stained slides were not available, Jones’ stained slides were
scored instead. Of note, more than one lesion could be
present on light microscopy in any one glomerulus, e.g.
segmental sclerosis and ischaemia/collapse could coexist
in the same glomerulus, and both features were then scored
as ‘present’ for that glomerulus. From our experience, opti-
mal slides for scoring should ideally include>10 glomeruli
for light microscopic assessment, and at least 3 glomeruli
for semi-thin section scoring.
Light microscopic slide scoring
Glomeruli that could not be scored due to, for instance,
incomplete sections or global sclerosis were indicated in the
box as ‘indeterminate’ for scoring. Glomeruli with <25%
of the tuft represented in the section were also marked as
‘indeterminate’ for vacuolization scoring. The total was
calculated as a sum of all scored and non-scored glomeruli.
Podocyte vacuolization was scored for each individual
glomerulus (‘0’ none, and ‘1’, ‘2’, or ‘3’, respectively, when
<25%, 25–50%, and>50% of podocytes showed cytoplas-
mic vacuoles). A final average scorewas calculated for each
biopsy.
The total number of glomeruliwithout any degree of scle-
rosis, as well as with no adhesions, evidence of ischaemia
or periglomerular fibrosis, was counted and reported as
nonsclerotic glomeruli. Segmental sclerosis was defined
as obliteration of capillary lumen with a increased ma-
trix involving a portion of the glomerulus (<50%, ‘mild’;
or ≥50% of the tuft affected, ‘severe’). Global sclero-
sis was scored when the entire glomerular tuft was scle-
rosed. Adhesions were scored when there was continuity
of connective tissue between the glomerular tuft and Bow-
man’s capsule without concomitant well-defined sclerosis.
Ischaemia/collapsewas scoredwhen>50%of the glomeru-
lar tuft showed corrugation of the glomerular basement
membrane and retraction of the tuft. Periglomerular fibro-
sis and/or Bowman’s capsule reduplication were defined
as present when >25% of the circumference of Bowman’s
capsule was affected by these processes, in the absence of
global glomerulosclerosis.
Of note, as a consequence of our definition of non-
sclerotic glomeruli, the sum of the percentages of glob-
ally and segmentally sclerotic glomeruli and non-sclerotic
glomeruli is not mathematically 100%.
Arterial sclerosis was scored based on lesions in vessels
as an average and also as a separate score for the most
severely affected as described by Remuzzi et al. [36]: ‘0’,
vascular lesions absent; ‘1+’, wall thickness increased but
to a degree less than the diameter of the lumen; ‘2+’, wall
thickness equal or slightly greater than the diameter of the
lumen; and ‘3+’, wall thickness far exceeding the diameter
of the lumen with extreme luminal narrowing or occlusion.
Arteriolar or arterial hyalinosis was scored as ‘present’ or
‘absent’ and specified as involving the media or suben-
dothelial location.
Interstitial fibrosis was semi-quantitatively estimated
on cortical tissue. Interstitial inflammation was noted as
‘present’ or ‘absent’. If present, its location in scarred ar-
eas or non-scarred areas or both was noted. However, this
parameter was variably scored. Any area involved with ei-
ther tubular atrophy and/or interstitial fibrosis was scored
as ‘involved with interstitial fibrosis’. Each ×20 field was
assessed, and degree of involvement with interstitial fibro-
sis estimated. An average of all cortical fields was then
calculated, and scored as the nearest 10%, except for mini-
mal fibrosis of ≤5%, which was scored as 5%. The results
were compared with morphometric assessment on the same
slides by the method published by Howie et al. [21].
Additional scoring was done on the epoxy-embedded
toluidine blue-stained semi-thin section slides. The number
of glomeruli available on the single section was designated.
The extent of segmental and global sclerosis, defined as
above, was noted. A podocyte inclusion score (see below)
was given separately for each glomerulus, and an average
score was thereby calculated for each biopsy. Podocyte in-
clusions were scored as follows: ‘0’, no deposits; ‘1+’, rare
small inconspicuous deposits; ‘2+’, more frequent small
deposits; ‘3+’, <50% of the tuft involved with large ex-
panded deposits in the presence or absence of concurrent
small deposits; and ‘4+’, ≥50% of the tuft involved with
large expanded deposits. Inclusions in parietal epithelial,
proximal and distal tubular, peritubular capillary, vascular
intimal and vascular medial cells were scored as ‘present’,
‘absent’ or ‘not sampled’ in the specimen.
Morphometric assessment of chronic renal damage
Each biopsy specimen was examined to give a measure of
the amount of chronic damage called ‘the index of chronic
damage’ [21]. Briefly, images of the cortex were captured
on a computer, and areas with chronic damage, defined as
globally sclerosed glomeruli, atrophic tubules and intersti-
tial fibrosis, were outlined using an interactive image anal-
ysis program. The index of chronic damage in a specimen
was the total cross-sectional area with chronic damage ex-
pressed as a percentage of the cortical cross-sectional area.
The mean estimates of the extent of interstitial fibrosis
were compared with the index of chronic damage in two
ways, firstly by calculation of the Spearman’s correlation
coefficient, and secondly by assessment of the agreement
between them using the Bland–Altman method [28]. This
method gave the mean difference, or bias, with 95% con-
fidence interval, and the limits of agreement, which were
two standard deviations of the difference on each side of
the mean difference. Preliminary analysis of 20 specimens
showed that exclusion of the area of globally sclerosed
glomeruli, which was not included in semi-quantitative es-
timation of the extent of interstitial fibrosis, made little
difference to the index of chronic damage, because inclu-
sion of globally sclerosed glomeruli added only 1% to the
index. Subjective scoring of interstitial fibrosis was gen-
erally recorded to the nearest 10%, or to 5% for minimal
fibrosis, and so 1% on the index was considered insignifi-
cant. The values of themorphometric index usedwere those
including the area of globally sclerosed glomeruli.
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